Modern medication of uterine myoma
Abstract
Myoma of the uterus is traditionally considered a surgical disease. Indeed, until recently the possibility of drug therapy for leiomyomas was extremely limited and included only preoperative preparation and prevention of the growth of small asymptomatic nodes. The breakthrough occurred after the introduction into clinical practice of selective modulators of progesterone receptors and the main representative of this group of drugs - ulipristal acetate. The article presents the results of preclinical trials, randomized controlled trials and the author s own experience in the treatment of uterine fibroids with the use of ulipristal acetate. The data accumulated so far allow us to state that the use of overground acetate is not only a good method of preoperative preparation of patients with uterine myoma, but also a worthy alternative to surgical treatment in patients planning fertility or refusing surgery.
About the Author
A. L. Tikhomirov
Moscow State Medical and Stomatological University n.a. A. I. Evdokimov
Russian Federation
Russian Federation
References
1. Тихомиров А. Л., Манухина Е. И., Вученович Ю.Д., Казенашев В. В., Бгажнокова М. В. Миома матки. Дифференцированный лечебный подход. Учебное пособие для врачей акушеров-гинекологов. Москва, 2015. 84 с.
2. Tan YH, Lethaby A. Preoperative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding. Cochrane Database Syst. Rev. 2013; 11: CD 010241.
3. Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol. Cell Endocrinol. 2012; 358: 223-231.
4. PEARL I Study Group. Donnez J, Tatarchuk TF, Bouchard P, e t a l. Ulipristal acetate versus placebo for fibroid treatment before surgery. N. Engl. J. Med. 2012; 366:409-420.
5. PEARL II Study Group. Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N. Engl. J. Med. 2012; 366: 421-432.
6. Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil. Steril. 2015; 103: 519-527.
7. Tsigkou A, Reis FM, Lee MH, et al. Increased progesterone receptor expression in uterine leiomyoma: correlation with age, number of leiomyomas, and clinical symptoms. Fertil. Steril. 2015; 104: 170-175.
8. Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil. Steril. 2011; 96: 1175-1189.
9. Bestel E, Donnez J. The potential of selective progesterone receptor modulators for the treatment of uterine fibroids. Expert Rev. Endocrinol. Metab. 2014; 9: 79-92.
10. Courtoy G, Donnez J, Marbaix E, Dolmans MM. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil. Steril. 2015; 104: 426-434.
11. Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int. J. Gynecol. Pathol. 2012; 31: 556-569.
12. Maruo T, Ohara N, Yoshida S, et al. Lessons learned from the preclinical drug discovery of asoprisnil and ulipristal for non-surgical treatment of uterine leiomyomas. Expert Opin. Drug Discov. 2011; 6: 897-911.
13. Donnez J, Donnez O, Dolmans MM. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice? Fertil. Steril. 2014; 102: 640-648.
14. Islam MS, Protic O, Giannubilo SR, e t a l. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J. Clin. Endocrinol. Metab. 2013; 98: 921-934.
15. Luyckx M, Squifflet JL, Jadoul P, et al. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil. Steril. 2014; 102: 1404-1409.
Review
For citations:
Tikhomirov A.L. Modern medication of uterine myoma. Medical alphabet. 2017;2(10):17-22. (In Russ.)
Views:
380
Email this article 